INVENT endorsed RENOVE study (REduced dose versus full dose of direct oral anticoagulant after uNprOvoked Venous thromboembolism) has now been registered in ClinicalTrials database and approved by the Drug French Agency and national ethics board! The study is expected to start on October 30, 2017 and is looking for potential sites and investigators. Click here to learn more about the study and how to participate!
